Identification

Name
Balsalazide
Accession Number
DB01014  (APRD00141)
Type
Small Molecule
Groups
Approved, Investigational
Description

Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.

The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.

Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.

Structure
Thumb
Synonyms
  • (e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid
  • (e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid
  • 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid
  • 5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
  • Balsalazida
  • Balsalazido
  • Balsalazidum
Product Ingredients
IngredientUNIICASInChI Key
Balsalazide disodium1XL6BJI034150399-21-6XDCNKOBSQURQOZ-MVIJUDHYSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ColazalCapsule750 mg/1OralCardinal Health2000-07-182018-03-22Us
GiazoTablet, film coated1.1 g/1OralSalix Pharmaceuticals2012-02-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Balsalazide DisodiumCapsule750 mg/1OralAv Pak2014-11-06Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralClinical Solutions Wholsesale2000-07-182017-11-02Us
Balsalazide DisodiumCapsule750 mg/1OralWest Ward Pharmaceutical2007-12-28Not applicableUs0054 007920180814 13942 72nj96
Balsalazide DisodiumTablet1.1 g/1OralPar Pharmaceutical2015-07-01Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralAv Kare, Inc.2016-06-29Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralApotex Corporation2007-12-28Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralGsms, Incorporated2018-01-26Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralPhysicians Total Care, Inc.2010-08-18Not applicableUs
Balsalazide DisodiumCapsule750 mg/1OralAmerincan Health Packaging2014-07-272018-07-31Us
Balsalazide DisodiumCapsule750 mg/1OralOceanside Pharmaceuticals2000-07-18Not applicableUs
International/Other Brands
Colazide
Categories
UNII
P80AL8J7ZP
CAS number
80573-04-2
Weight
Average: 357.3175
Monoisotopic: 357.096085227
Chemical Formula
C17H15N3O6
InChI Key
IPOKCKJONYRRHP-FMQUCBEESA-N
InChI
InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+
IUPAC Name
5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid
SMILES
OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O

Pharmacology

Indication

For the treatment of mildly to moderately active ulcerative colitis.

Associated Conditions
Pharmacodynamics

Balsalazide is a prodrug that has little or no pharmacologic activity until it is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the intert 4-aminobenzoyl-(beta)-alanine. As a result, the spectrum of pharmacologic activity of balsalazide is similar to that of mesalamine.

Mechanism of action

The mechanism of action of 5-aminosalicylic acid is unknown, but appears exert its anti-inflammatory effects locally (in the GI tract) rather than systemically. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (catalyzes the formation of prostaglandin precursors from arachidonic acid), and through the lipoxygenase pathways (catalyzes the formation of leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid and its metabolites), is increased in patients with chronic inflammatory bowel disease. Therefore, it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon through both the inhibition of cyclooxygenase and lipoxygenase.

TargetActionsOrganism
APeroxisome proliferator-activated receptor gamma
agonist
Human
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
AArachidonate 5-lipoxygenase
inhibitor
Human
Absorption

Low and variable, intact balsalazide is poorly absorbed systemically.

Volume of distribution
Not Available
Protein binding

≥99%

Metabolism

Cleaved in the colon via bacterial azoreduction to 5–aminosalicylic acid (5–ASA) and 4–aminobenzoyl-beta-alanine, the inactive carrier moiety.

Route of elimination

The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.

Half life

Half-life could not be determined.

Clearance
Not Available
Toxicity

A single oral dose of balsalazide disodium at 5 grams/kg or 4-aminobenzoyl-(beta)-alanine, a metabolite of balsalazide disodium, at 1 gram/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Balsalazide.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Balsalazide is combined with 5-androstenedione.Experimental, Illicit
AbciximabBalsalazide may increase the anticoagulant activities of Abciximab.Approved
AcarboseBalsalazide may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololBalsalazide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBalsalazide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Balsalazide.Experimental
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Balsalazide.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Balsalazide.Experimental
AlbiglutideBalsalazide may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Balsalazide.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.Approved
AliskirenBalsalazide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Balsalazide.Experimental
AlogliptinBalsalazide may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aloxiprin.Experimental
AlprenololBalsalazide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Balsalazide.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideBalsalazide may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Balsalazide.Approved
Ammonium chlorideThe serum concentration of Balsalazide can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Balsalazide.Approved
AncrodBalsalazide may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Balsalazide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Balsalazide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Balsalazide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Balsalazide.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Balsalazide is combined with Antipyrine.Approved, Investigational
Antithrombin III humanBalsalazide may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Balsalazide is combined with Antrafenine.Approved
ApixabanBalsalazide may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Balsalazide.Investigational
ApramycinBalsalazide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Balsalazide.Approved, Investigational
ArbekacinBalsalazide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinBalsalazide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBalsalazide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBalsalazide may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineBalsalazide may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Atamestane.Investigational
AtenololBalsalazide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Balsalazide.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Balsalazide.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Balsalazide.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Balsalazide is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Balsalazide.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Balsalazide.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Bacitracin.Approved, Vet Approved
BatroxobinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Batroxobin.Experimental
BazedoxifeneBalsalazide may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminBalsalazide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololBalsalazide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinBalsalazide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Balsalazide.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Balsalazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Balsalazide.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Balsalazide.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Balsalazide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Balsalazide.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Balsalazide.Approved, Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Balsalazide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Betamethasone.Approved, Vet Approved
BetaxololBalsalazide may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Balsalazide.Approved, Investigational
BevantololBalsalazide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Balsalazide.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BisoprololBalsalazide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBalsalazide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBalsalazide may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Balsalazide.Approved
BromocriptineBalsalazide may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Balsalazide.Investigational
BucindololBalsalazide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Balsalazide is combined with Bufexamac.Approved, Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Balsalazide.Experimental
BufuralolBalsalazide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Balsalazide.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Balsalazide.Approved
BupranololBalsalazide may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Balsalazide.Investigational
CanagliflozinBalsalazide may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Balsalazide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Balsalazide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Balsalazide.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Balsalazide is combined with Caplacizumab.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Balsalazide.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Balsalazide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Balsalazide.Approved, Vet Approved, Withdrawn
CarteololBalsalazide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBalsalazide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Balsalazide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Balsalazide.Approved, Investigational
CeliprololBalsalazide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBalsalazide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Balsalazide.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
ChlorotrianiseneBalsalazide may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpropamideBalsalazide may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Balsalazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Balsalazide.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cimicoxib.Investigational
CinoxacinBalsalazide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinBalsalazide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Balsalazide.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Balsalazide.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Balsalazide.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Balsalazide.Vet Approved
CloranololBalsalazide may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Balsalazide.Experimental
ClorindioneBalsalazide may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensBalsalazide may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Balsalazide.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Balsalazide.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Balsalazide is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Balsalazide.Experimental
Dabigatran etexilateBalsalazide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinBalsalazide may increase the thrombogenic activities of Daidzein.Experimental
DalteparinBalsalazide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBalsalazide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinBalsalazide may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Balsalazide.Investigational
DarexabanBalsalazide may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Balsalazide is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Balsalazide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Balsalazide is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Balsalazide.Investigational
DersalazineBalsalazide may increase the anticoagulant activities of Dersalazine.Investigational
DesipramineBalsalazide may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinBalsalazide may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Balsalazide.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Balsalazide.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Balsalazide.Experimental
DextranBalsalazide may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinBalsalazide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Balsalazide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Diclofenamide.Approved, Investigational
DicoumarolBalsalazide may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolBalsalazide may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolBalsalazide may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Balsalazide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Balsalazide.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Balsalazide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Balsalazide.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Balsalazide.Approved
DihydrostreptomycinBalsalazide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Balsalazide.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Balsalazide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Balsalazide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Balsalazide.Approved
DiphenadioneBalsalazide may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Balsalazide.Approved
DisopyramideBalsalazide may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dorzolamide.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Balsalazide.Approved
DrospirenoneBalsalazide may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Balsalazide is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Balsalazide is combined with Droxicam.Withdrawn
DulaglutideBalsalazide may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the antiplatelet activities of Balsalazide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Balsalazide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Balsalazide.Investigational
Edetic AcidBalsalazide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBalsalazide may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Balsalazide.Approved, Investigational
EmpagliflozinBalsalazide may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Balsalazide is combined with Enalaprilat.Approved
EnoxacinBalsalazide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinBalsalazide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Balsalazide.Experimental
EpanololBalsalazide may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolBalsalazide may increase the thrombogenic activities of Epimestrol.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Balsalazide.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Balsalazide.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Balsalazide.Experimental
EplerenoneBalsalazide may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Balsalazide.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Balsalazide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Balsalazide.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Balsalazide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Balsalazide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Equilin.Approved
EquolBalsalazide may increase the thrombogenic activities of Equol.Investigational
EsatenololBalsalazide may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Balsalazide.Approved, Investigational
EsmololBalsalazide may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateBalsalazide may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateBalsalazide may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateBalsalazide may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolBalsalazide may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedBalsalazide may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Balsalazide.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Balsalazide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Balsalazide.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateBalsalazide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Balsalazide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Balsalazide.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Balsalazide.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Balsalazide.Investigational, Nutraceutical
ExenatideBalsalazide may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Balsalazide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Balsalazide.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Balsalazide.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Balsalazide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Balsalazide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Balsalazide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Balsalazide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Balsalazide.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Balsalazide.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Balsalazide.Approved, Investigational
FleroxacinBalsalazide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Balsalazide.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fludrocortisone.Approved, Investigational
FluindioneBalsalazide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineBalsalazide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Balsalazide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Balsalazide.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Balsalazide.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Balsalazide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Balsalazide.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone propionate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Balsalazide.Approved, Nutraceutical, Vet Approved
FondaparinuxBalsalazide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Balsalazide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Fosinopril.Approved
FramycetinBalsalazide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
GabexateBalsalazide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBalsalazide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBalsalazide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Balsalazide.Approved, Withdrawn
GemifloxacinBalsalazide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBalsalazide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinBalsalazide may increase the thrombogenic activities of Genistein.Investigational
GentamicinBalsalazide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABalsalazide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Balsalazide.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Balsalazide.Experimental
GliclazideBalsalazide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBalsalazide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBalsalazide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideBalsalazide may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinBalsalazide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Balsalazide.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Balsalazide.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Balsalazide is combined with HE3286.Investigational
Hemoglobin crosfumarilBalsalazide may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Heparin.Approved, Investigational
HexestrolBalsalazide may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Balsalazide.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Balsalazide.Approved, Investigational
HydralazineBalsalazide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Balsalazide.Investigational
Hygromycin BBalsalazide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Balsalazide.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Balsalazide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Balsalazide.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Balsalazide is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Balsalazide.Approved, Investigational, Nutraceutical
IdraparinuxBalsalazide may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Balsalazide.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Balsalazide.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Balsalazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Balsalazide.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Balsalazide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide.Approved
IndenololBalsalazide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Balsalazide.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Balsalazide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Balsalazide.Withdrawn
Insulin AspartBalsalazide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirBalsalazide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineBalsalazide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineBalsalazide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanBalsalazide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproBalsalazide may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Balsalazide.Approved, Investigational
IsepamicinBalsalazide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Balsalazide.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Balsalazide.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Balsalazide is combined with Istaroxime.Investigational
KanamycinBalsalazide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Balsalazide.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Balsalazide.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Balsalazide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Balsalazide.Approved
LabetalolBalsalazide may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Balsalazide.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Balsalazide.Experimental
LandiololBalsalazide may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Balsalazide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Balsalazide.Approved, Investigational
LepirudinBalsalazide may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Balsalazide.Approved, Investigational
LetaxabanBalsalazide may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololBalsalazide may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololBalsalazide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBalsalazide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Balsalazide.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Balsalazide.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Balsalazide.Experimental
LiraglutideBalsalazide may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Balsalazide.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Balsalazide.Experimental
LomefloxacinBalsalazide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Balsalazide.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Balsalazide.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Balsalazide.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Balsalazide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Balsalazide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Balsalazide.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Balsalazide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Balsalazide is combined with ME-609.Investigational
MecaserminBalsalazide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Balsalazide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Balsalazide.Approved
MelagatranBalsalazide may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Balsalazide.Approved, Vet Approved
MepindololBalsalazide may decrease the antihypertensive activities of Mepindolol.Experimental
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Balsalazide.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Balsalazide.Approved
MestranolBalsalazide may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Balsalazide.Approved, Investigational, Withdrawn
MetforminBalsalazide may increase the hypoglycemic activities of Metformin.Approved
MethallenestrilBalsalazide may increase the thrombogenic activities of Methallenestril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Balsalazide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.Approved
Methyl salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Balsalazide is combined with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Balsalazide.Experimental
MetipranololBalsalazide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide.Approved
MetoprololBalsalazide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Balsalazide.Investigational, Withdrawn
MicronomicinBalsalazide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Balsalazide.Approved, Experimental
MifepristoneBalsalazide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolBalsalazide may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Balsalazide.Approved, Investigational
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Balsalazide.Approved
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Balsalazide.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Balsalazide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Balsalazide.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Balsalazide.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Balsalazide.Approved
MoxestrolBalsalazide may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinBalsalazide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Balsalazide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Balsalazide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Balsalazide.Approved
NadololBalsalazide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBalsalazide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Balsalazide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Balsalazide.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Balsalazide.Investigational
Nalidixic AcidBalsalazide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Balsalazide.Approved, Vet Approved
NateglinideBalsalazide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Balsalazide is combined with NCX 1022.Investigational
NeamineBalsalazide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololBalsalazide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Balsalazide.Approved, Withdrawn
NemonoxacinBalsalazide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Balsalazide.Approved, Investigational
NetilmicinBalsalazide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Balsalazide.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Balsalazide.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Balsalazide.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Balsalazide.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Balsalazide.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Balsalazide.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Balsalazide.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Balsalazide.Investigational
NorfloxacinBalsalazide may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinBalsalazide may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Balsalazide.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Balsalazide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Balsalazide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Balsalazide.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Balsalazide is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Balsalazide is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Balsalazide.Vet Approved
OtamixabanBalsalazide may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Balsalazide.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Balsalazide.Approved
Oxolinic acidBalsalazide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololBalsalazide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Balsalazide.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ozagrel.Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Balsalazide.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Balsalazide.Approved, Investigational
PazufloxacinBalsalazide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBalsalazide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBalsalazide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateBalsalazide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineBalsalazide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateBalsalazide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Balsalazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Perindopril.Approved
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Balsalazide.Experimental
PhenindioneBalsalazide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBalsalazide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateBalsalazide may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Balsalazide.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Balsalazide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Balsalazide.Approved, Investigational
PindololBalsalazide may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneBalsalazide may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidBalsalazide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Balsalazide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Balsalazide.Approved, Investigational
Piromidic acidBalsalazide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Balsalazide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Balsalazide.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorBalsalazide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinBalsalazide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateBalsalazide may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Balsalazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pomalidomide.Approved
Potassium CitrateBalsalazide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololBalsalazide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Balsalazide.Approved, Investigational
PramlintideBalsalazide may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Balsalazide.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Balsalazide.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Balsalazide can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Balsalazide.Experimental
PromestrieneBalsalazide may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Balsalazide.Approved, Investigational
PropafenoneBalsalazide may decrease the antihypertensive activities of Propafenone.Approved
PropranololBalsalazide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Balsalazide.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Balsalazide.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Balsalazide.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Balsalazide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Balsalazide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Balsalazide.Vet Approved
Protein CBalsalazide may increase the anticoagulant activities of Protein C.Approved
Protein S humanBalsalazide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBalsalazide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBalsalazide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Balsalazide.Investigational
PuromycinBalsalazide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Quinapril.Approved, Investigational
QuinestrolBalsalazide may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Balsalazide.Approved
QuinineBalsalazide may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Balsalazide.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ramipril.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Balsalazide.Investigational
RepaglinideBalsalazide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Balsalazide is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Reteplase.Approved, Investigational
ReviparinBalsalazide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinBalsalazide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Balsalazide.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Risedronate.Approved, Investigational
RivaroxabanBalsalazide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Balsalazide.Approved, Investigational, Withdrawn
RosiglitazoneBalsalazide may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosoxacinBalsalazide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinBalsalazide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Balsalazide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Balsalazide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Balsalazide.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Balsalazide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Balsalazide.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Balsalazide.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Balsalazide.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Saruplase.Experimental
SaxagliptinBalsalazide may increase the hypoglycemic activities of Saxagliptin.Approved
SecoisolariciresinolBalsalazide may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Balsalazide is combined with Selexipag.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Balsalazide is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Balsalazide.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Balsalazide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Balsalazide.Investigational
SertralineSertraline may increase the antiplatelet activities of Balsalazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Balsalazide.Approved, Vet Approved
SisomicinBalsalazide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinBalsalazide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinBalsalazide may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateThe risk or severity of bleeding can be increased when Balsalazide is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Balsalazide.Approved
SotalolBalsalazide may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinBalsalazide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Balsalazide.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Streptokinase.Approved, Investigational
StreptomycinBalsalazide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineBalsalazide may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleBalsalazide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Balsalazide.Approved
SulfisoxazoleBalsalazide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Balsalazide.Approved, Investigational
SulodexideBalsalazide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Balsalazide.Investigational
SunitinibBalsalazide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Balsalazide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Balsalazide.Experimental
Synthetic Conjugated Estrogens, ABalsalazide may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BBalsalazide may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusBalsalazide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Balsalazide.Approved
TalinololBalsalazide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Balsalazide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Balsalazide.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Balsalazide.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Balsalazide.Approved, Investigational
TemafloxacinBalsalazide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Balsalazide.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Balsalazide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Balsalazide.Vet Approved
TerbutalineBalsalazide may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Balsalazide.Approved
TertatololBalsalazide may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Balsalazide.Investigational
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Balsalazide.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tiaprofenic acid.Approved
TiboloneBalsalazide may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Balsalazide.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololBalsalazide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Balsalazide.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tinzaparin.Approved
TioclomarolBalsalazide may increase the anticoagulant activities of Tioclomarol.Experimental
TioguanineThe metabolism of Tioguanine can be decreased when combined with Balsalazide.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Balsalazide.Approved
TixocortolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tixocortol.Approved, Withdrawn
TobramycinBalsalazide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideBalsalazide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideBalsalazide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Balsalazide.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Balsalazide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Balsalazide is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Balsalazide.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Balsalazide.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Balsalazide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Balsalazide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Balsalazide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBalsalazide may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Balsalazide.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Balsalazide.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Balsalazide.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Balsalazide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Balsalazide is combined with Trolamine salicylate.Approved
TrovafloxacinBalsalazide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinBalsalazide may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Balsalazide.Approved, Investigational
UrokinaseThe risk or severity of adverse effects can be increased when Balsalazide is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Balsalazide.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Balsalazide.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide.Approved, Investigational
VancomycinBalsalazide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Balsalazide.Approved
VerapamilVerapamil may increase the anticoagulant activities of Balsalazide.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Balsalazide.Approved
WarfarinBalsalazide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBalsalazide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Balsalazide.Approved, Investigational
ZeranolBalsalazide may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Balsalazide.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Balsalazide.Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Balsalazide.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Balsalazide.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Eckardt C. G. Wolf, Nageib Mohamed, Bhaskar Reddy Guntoori, "Safe process for the preparation of balsalazide." U.S. Patent US07271253, issued September 18, 2007.

US07271253
General References
  1. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890]
  2. Ragunath K, Williams JG: Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. [PubMed:11563993]
External Links
Human Metabolome Database
HMDB0015149
PubChem Compound
6335412
PubChem Substance
46505592
ChemSpider
10662422
ChEBI
267413
ChEMBL
CHEMBL1201346
Therapeutic Targets Database
DAP000733
PharmGKB
PA448536
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Balsalazide
ATC Codes
A07EC04 — Balsalazide
FDA label
Download (44.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
3CompletedSupportive CareInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
3CompletedTreatmentInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)2

Pharmacoeconomics

Manufacturers
  • Apotex inc etobicoke site
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Salix pharmaceuticals inc
Packagers
  • Apotex Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Physicians Total Care Inc.
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Salix Pharmaceuticals
Dosage forms
FormRouteStrength
CapsuleOral750 mg/1
TabletOral1.1 g/1
Tablet, film coatedOral1.1 g/1
Prices
Unit descriptionCostUnit
Colazal 750 mg capsule2.82USD capsule
Balsalazide disodium 750 mg capsule1.54USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7452872Yes2007-02-242027-02-24Us
US7625884Yes2007-02-242027-02-24Us
US6197341No1998-03-132018-03-13Us
US8497256No2011-06-232031-06-23Us
US9192616No2006-08-022026-08-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble as disodium saltNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0621 mg/mLALOGPS
logP3.37ALOGPS
logP3.17ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.06ChemAxon
pKa (Strongest Basic)-0.033ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area148.65 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity94.37 m3·mol-1ChemAxon
Polarizability35.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8947
Blood Brain Barrier+0.7807
Caco-2 permeable-0.6455
P-glycoprotein substrateNon-substrate0.6247
P-glycoprotein inhibitor INon-inhibitor0.7877
P-glycoprotein inhibitor IINon-inhibitor0.7615
Renal organic cation transporterNon-inhibitor0.8312
CYP450 2C9 substrateNon-substrate0.7932
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.5523
CYP450 1A2 substrateNon-inhibitor0.7689
CYP450 2C9 inhibitorNon-inhibitor0.7883
CYP450 2D6 inhibitorNon-inhibitor0.8726
CYP450 2C19 inhibitorNon-inhibitor0.8153
CYP450 3A4 inhibitorNon-inhibitor0.9537
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9196
Ames testNon AMES toxic0.5593
CarcinogenicityNon-carcinogens0.75
BiodegradationNot ready biodegradable0.5575
Rat acute toxicity1.9986 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9148
hERG inhibition (predictor II)Non-inhibitor0.7772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azobenzenes
Sub Class
Not Available
Direct Parent
Azobenzenes
Alternative Parents
Beta amino acids and derivatives / Salicylic acids / Benzamides / Benzoic acids / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Dicarboxylic acids and derivatives / Vinylogous acids / Secondary carboxylic acid amides / Azo compounds
show 6 more
Substituents
Azobenzene / Beta amino acid or derivatives / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid / Benzoic acid or derivatives / Benzamide / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monohydroxybenzoic acid (CHEBI:267413)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Tursi A: Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1555-63. doi: 10.1517/17425250903228842. [PubMed:19708827]
  2. Iacucci M, de Silva S, Ghosh S: Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010 Feb;24(2):127-33. [PubMed:20151072]
  3. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423]
  4. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890]
  4. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008 Feb 1;75(3):668-76. Epub 2007 Sep 29. [PubMed:17981262]
  5. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890]
  4. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890]
  2. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K: 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions. 1992;Spec No:C37-46. [PubMed:1359745]

Enzymes

Kind
Protein
Organism
Bacillus sp. (strain OY1-2)
Pharmacological action
Unknown
Actions
Substrate
General Function
Azobenzene reductase activity
Specific Function
Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADPH as an electron donor for its activity. Compounds with paired naphthalene groups co...
Gene Name
azr
Uniprot ID
Q9FAW5
Uniprot Name
NADPH azoreductase
Molecular Weight
19293.155 Da
References
  1. Ragunath K, Williams JG: Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. [PubMed:11563993]
  2. Ryan A, Laurieri N, Westwood I, Wang CJ, Lowe E, Sim E: A novel mechanism for azoreduction. J Mol Biol. 2010 Jul 2;400(1):24-37. doi: 10.1016/j.jmb.2010.04.023. Epub 2010 Apr 24. [PubMed:20417637]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:44